Fig. 4

Acetylcholine/CHRNA5 axis-mediated CAMKII activation suppresses GSK-3β activity to stabilize β-catenin. a, b WB-based detection of the half-life of β-catenin in CHRNA5 silencing or overexpressing ICC cells treated with CHX. c, d WB-based detection of p-β-catenin and p-s9-GSK3β in CHRNA5 silencing or overexpressing ICC cells. e WB-based detection of β-catenin expression level in CHRNA5 silencing ICC cells treated with GSK3β inhibitor LiCl. f Transwell assay-based detection of the migration ability in CHRNA5 silencing ICC cells treated with GSK3β inhibitor LiCl. g WB-based detection of β-catenin expression level in CHRNA5 overexpressing ICC cells in the condition of overexpressing WT-GSK3β or mutant-GSK3β(S9A). h Transwell assay-based detection of the migration ability in CHRNA5 overexpressing ICC cells in the condition of overexpressing WT-GSK3β or mutant-GSK3β(S9A). i WB-based detection of p-CAMKII expression level in CHRNA5 silencing or overexpressing ICC cells. j WB-based detection of CAMKII coprecipitated with GSK3β. k WB-based detection of CAMKII coprecipitated with GSK3β in CHRNA5 silencing or overexpressing ICC cells. l WB-based detection of β-catenin and p-s9-GSK3β expression level in ICC cells treated with KN93. Representative results from at least three experiments are shown. Data are shown as means ± SD. *p < 0.05, **p < 0.005